| 000 | 01384 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250518014425.0 | ||
| 264 | 0 | _c20191112 | |
| 008 | 201911s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/s41416-018-0363-8 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Can | |
| 245 | 0 | 0 |
_aDynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _c02 2019 |
||
| 300 |
_a346-355 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aBiomarkers, Pharmacological _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aInterferon-gamma _xblood |
| 650 | 0 | 4 |
_aLymphocytes _xmetabolism |
| 650 | 0 | 4 |
_aMelanoma, Experimental _ximmunology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 |
_aNivolumab _xadministration & dosage |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 700 | 1 | _aHe, Hua | |
| 700 | 1 | _aLi, Xiaobing | |
| 700 | 1 | _aSu, Maureen A | |
| 700 | 1 | _aCao, Yanguang | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 120 _gno. 3 _gp. 346-355 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/s41416-018-0363-8 _zAvailable from publisher's website |
| 999 |
_c29200137 _d29200137 |
||